ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
LeadLI
LB Investment
Activity from announced rounds
Activity in this selectionOct 18, 2026 · Sep 19, 2026
LB Investment is the Korean investment firm identified as lead by ImpriMed and associated with partner Kiho Park.
Recorded funding activity
ImpriMed tests live cancer cells against medicines and combines the results with clinical data. Point2 develops interconnect hardware, while CarbonSix develops robotic intelligence for manufacturing. These companies retain their distinct products and participant roles.
- Rounds participated in
- 1
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $10M 1 disclosed · full round size, not this investor’s share